The Procter & Gamble Company (NYSE:PG – Get Rating) saw unusually large options trading activity on Wednesday. Investors bought 42,480 put options on the stock. This is an increase of approximately 66% compared to the typical volume of 25,517 put options.
Procter & Gamble Stock Performance
Shares of PG stock opened at $141.72 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.37 and a current ratio of 0.56. The firm has a market cap of $334.34 billion, a price-to-earnings ratio of 24.86, a P/E/G ratio of 3.93 and a beta of 0.42. Procter & Gamble has a 52 week low of $122.18 and a 52 week high of $164.98. The firm's 50-day simple moving average is $149.14 and its two-hundred day simple moving average is $141.99.
Get
Procter & Gamble alerts:
Procter & Gamble (NYSE:PG – Get Rating) last posted its quarterly earnings results on Thursday, January 19th. The company reported $1.59 EPS for the quarter, topping analysts' consensus estimates of $1.58 by $0.01. Procter & Gamble had a net margin of 17.79% and a return on equity of 32.03%. The company had revenue of $20.77 billion for the quarter, compared to analysts' expectations of $20.75 billion. During the same quarter in the previous year, the firm posted $1.66 EPS. Procter & Gamble's revenue was down .9% on a year-over-year basis. As a group, equities analysts forecast that Procter & Gamble will post 5.84 earnings per share for the current year.
Procter & Gamble Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 15th. Stockholders of record on Friday, January 20th will be paid a dividend of $0.9133 per share. The ex-dividend date of this dividend is Thursday, January 19th. This represents a $3.65 annualized dividend and a dividend yield of 2.58%. Procter & Gamble's payout ratio is 64.04%.
Analyst Ratings Changes
PG has been the topic of a number of analyst reports. Evercore ISI lowered their target price on shares of Procter & Gamble to $145.00 in a report on Thursday, October 20th. UBS Group lowered their price objective on Procter & Gamble from $153.00 to $135.00 in a research note on Thursday, October 13th. Morgan Stanley cut their target price on Procter & Gamble from $177.00 to $160.00 and set an "overweight" rating on the stock in a research report on Tuesday, October 4th. Wolfe Research started coverage on Procter & Gamble in a research report on Monday, November 21st. They issued an "outperform" rating and a $156.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft raised their price objective on Procter & Gamble from $156.00 to $162.00 and gave the company a "buy" rating in a research note on Tuesday, December 6th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Procter & Gamble currently has an average rating of "Moderate Buy" and a consensus target price of $153.00.
Insider Transactions at Procter & Gamble
In other Procter & Gamble news, CEO Sundar G. Raman sold 9,922 shares of Procter & Gamble stock in a transaction on Monday, November 21st. The shares were sold at an average price of $145.00, for a total value of $1,438,690.00. Following the completion of the sale, the chief executive officer now directly owns 12,312 shares of the company's stock, valued at $1,785,240. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CEO R. Alexandra Keith sold 33,968 shares of the stock in a transaction on Tuesday, November 8th. The stock was sold at an average price of $137.44, for a total value of $4,668,561.92. Following the transaction, the chief executive officer now directly owns 38,990 shares in the company, valued at approximately $5,358,785.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Sundar G. Raman sold 9,922 shares of the business's stock in a transaction on Monday, November 21st. The shares were sold at an average price of $145.00, for a total transaction of $1,438,690.00. Following the sale, the chief executive officer now owns 12,312 shares of the company's stock, valued at approximately $1,785,240. The disclosure for this sale can be found here. Insiders sold a total of 58,812 shares of company stock valued at $8,190,363 in the last quarter. 0.26% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Procter & Gamble
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PG. EWG Elevate Inc. bought a new position in Procter & Gamble in the 4th quarter worth about $26,000. Win Advisors Inc. grew its stake in Procter & Gamble by 91.5% during the second quarter. Win Advisors Inc. now owns 180 shares of the company's stock valued at $26,000 after acquiring an additional 86 shares in the last quarter. Legend Financial Advisors Inc. bought a new stake in Procter & Gamble during the 3rd quarter worth approximately $30,000. Bourgeon Capital Management LLC lifted its stake in Procter & Gamble by 39.9% in the 4th quarter. Bourgeon Capital Management LLC now owns 249 shares of the company's stock worth $38,000 after purchasing an additional 71 shares in the last quarter. Finally, Horizons Wealth Management bought a new position in shares of Procter & Gamble in the second quarter worth $52,000. 62.13% of the stock is currently owned by institutional investors.
About Procter & Gamble
(Get Rating)
Procter & Gamble Co engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric & Home Care, and Baby, Feminine & Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances.
Featured Stories
- Get a free copy of the StockNews.com research report on Procter & Gamble (PG)
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
Receive News & Ratings for Procter & Gamble Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Procter & Gamble and related companies with MarketBeat.com's FREE daily email newsletter.
